Skip to main content

Table 1 Patient characteristics

From: A phase I study of high-dose rosuvastatin with standard dose erlotinib in patients with advanced solid malignancies

  Concurrent Cohorts 1 and 2/Schedule A Alternating Schedule B All patients
Number of patients 18 6 24
Age (years)
 Median/range 60/43–70 54/44–63 58/43–70
Gender
 Male 11 (60 %) 4 (67 %) 15 (63 %)
 Female 7 (40 %) 2 (33 %) 9 (37 %)
Ethnicity
 Caucasian    23 (96 %)
 Other    1 (4 %)
Primary tumour
 NSCLC 5 2 7
 Esophageal 4   4
 Pancreas 2 1 3
 GU 4 2 6
 Colon 2   2
 Breast 1   1
 Unknown   1 1
Number Frequency Percent
Previous treatment regimens
 1 7 29.2
 2 8 33.3
 3 6 25.0
 >3 3 12.5
Reason Off protocol
 Progressive disease 19 79.2
 Adverse event 1 4.2
 Patient withdrawal 2 8.3
 Other 2 8.3